Dose-related differences in effectiveness of human papillomavirus vaccination against genital warts: A nationwide study of 550 000 young girls

Clinical Infectious Diseases

Volumn 61, Issue 5, 2015, Pages 676-682

  Blomberg, Maria ^a   Dehlendorff, Christian ^a   Sand, Carsten ^b   Kjaer, Susanne K ^a,c  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Condyloma acuminate; Dose response relationship; Genital warts; Human papillomavirus; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ARTICLE; CONDYLOMA ACUMINATUM; DENMARK; DRUG EFFICACY; FEMALE; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; TREATMENT RESPONSE; VACCINATION; ADULT; COHORT ANALYSIS; CONDYLOMATA ACUMINATA; DOSE RESPONSE; IMMUNOLOGY; MASS IMMUNIZATION; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; COHORT STUDIES; CONDYLOMATA ACUMINATA; DENMARK; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; MASS VACCINATION; PAPILLOMAVIRUS VACCINES; YOUNG ADULT;

EID: 84942057764     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ364     Document Type: Article

References (19)

1. Markowitz LE, Tsu V, Deeks SL, et al. Human papillomavirus vaccine introduction-the first five years. Vaccine 2012; 30(suppl 5): F139-48.
2. Giuliano AR, Tortolero-Luna G, Ferrer E, et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008; 26(suppl 10):K17-28.
3. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30(suppl 5):F123-38.
4. National Institute for Health Data and Disease Control. EPI-NEWS HPV-vaccination-coverage 2012. Available at: http://www.ssi.dk/English/News/EPI-NEWS/2013/No%2020%20-%202013. Accessed 13 May 2015.
5. World Health Organization. Evidence-based recommendations on human papilloma virus (HPV) vaccines schedules. Background paper for SAGE discussions, 2014. Available at: http://www.who.int/immunization/sage/meetings/2014/april/1-HPV-Evidence-based- recommendationsWHO-with-Appendices2-3.pdf?ua=1. Accessed 13 May 2015.
6. Blomberg M, Dehlendorff C, Munk C, Kjaer SK. Strongly decreased risk of genital warts after vaccination against HPV. Nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis 2013; 57:929-34.
7. Carstensen B, Plummer M, Hills M, Laara E. Epi: A package for statistical analysis in epidemiology. R package version 1.1.24. Available at: http://CRAN.R-project.org/package=Epi. Accessed 13 May 2015.
8. Plummer M, Carstensen B. Lexis: an R class for epidemiological studies with long-term follow-up. J Stat Software 2011; 38:1-12.
9. Carstensen B, Plummer M. Using Lexis objects for multi-state models in R. J Stat Software 2011; 38:1-18.
10. Stanley MA, Sudenga SL, Giuliano AR. Alternative dosage schedules with HPV virus-like particle vaccines. Expert Rev Vaccines 2014; 13:1027-38.
11. Romanowski B, Schwarz TF, Ferguson LM, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin 2011; 7:1374-86.
12. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013; 309:1793-802.
13. Donken R, Knol MJ, Bogaards JA, van der Klis FR, Meijer CJ, de Melker HE. Inconclusive evidence for non-inferior immunogenicity of twocompared with three-dose HPV immunization schedules in preadolescent girls: a systematic review and meta-analysis. J Infect 2015; 71:61-73.
14. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 25:4931-9.
15. Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013; 11:227.
16. Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014; 348:g1458.
17. Herweijer E, Leval A, Ploner A, et al. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA 2014; 311:597-603.
18. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011; 103:1444-51.
19. Safaeian M, Porras C, Pan Y, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica vaccine trial. Cancer Prev Res (Phila) 2013; 6:1242-50.